Rigel Pharmaceuticals Inc (RIGL)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $837.18M
Last updated: Nov 17, 2026 at 11:06 AM ET
Rigel Pharmaceuticals Inc (RIGL) P/E Ratio & Valuation History
Rigel Pharmaceuticals (RIGL) trades at 14.2x trailing earnings and 2.8x sales. Its P/S of 2.8x is above its 5-year median of 2.1x. Its forward P/E is 9.3x.
Current Multiples
Its forward P/E is below its trailing P/E, which implies earnings per share about 52.7% higher over the next year.
| Multiple | Value |
|---|---|
| P/E (trailing) | 14.2x |
| Forward P/E | 9.3x |
| Price to sales | 2.8x |
| Price to book | 1.8x |
| EV/EBITDA | 9.8x |
| PEG | N/A |
Historical Medians
Against its 10-year medians, its P/S is 30.0% below 4.0x.
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/S | 2.8x | 2.1x | 4.0x |
Valuation History
Over the 3 of the 10 year ends shown that have a P/E, its P/E ranged from 6.6x in 2025 to 378.6x in 2021.
| Year end | Price | P/E | P/S | P/B |
|---|---|---|---|---|
| 2025 | $42.83 | 6.6x | 2.6x | 2.1x |
| 2024 | $16.82 | 17.9x | 1.7x | 92.0x |
| 2023 | $14.50 | N/A | 2.2x | N/A |
| 2022 | $15.00 | N/A | 2.2x | N/A |
| 2021 | $26.50 | 378.6x | 3.0x | 14.9x |
| 2020 | $35.00 | N/A | 10.1x | 17.4x |
| 2019 | $21.40 | N/A | 6.0x | 6.7x |
| 2018 | $23.00 | N/A | 8.6x | 3.5x |
| 2017 | $38.80 | N/A | 61.0x | 5.6x |
| 2016 | $23.80 | N/A | 10.9x | 4.3x |
GNG Valuation
| GNG view | Fairly valued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About RIGL
What is RIGL's forward P/E ratio?
Rigel Pharmaceuticals has a forward P/E ratio of 9.3x.
Is RIGL stock overvalued?
GNG's valuation label for RIGL is Fairly valued.
What is RIGL's price to sales ratio?
Rigel Pharmaceuticals has a price to sales ratio of 2.8x.
RIGL pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors